mibefradil has been researched along with Cancer of Ovary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, S; Choi, DL; Choi, HE; Choi, HW; Huang, M; Jang, SJ; Kim, KS; Lee, JY; Lee, KT; Rhim, H; Rim, HK | 1 |
| Casarez, EV; Dziegielewska, B; Dziegielewski, J; Gray, LS; Slack-Davis, JK; Yang, WZ | 1 |
| Li, M; Li, W; Wang, N; Zhang, BB; Zhang, SL | 1 |
3 other study(ies) available for mibefradil and Cancer of Ovary
| Article | Year |
|---|---|
In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers.
Topics: Calcium Channel Blockers; Calcium Channels, T-Type; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Female; Humans; Ovarian Neoplasms; Quinazolines; Structure-Activity Relationship | 2013 |
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Calcium Channels, T-Type; Carboplatin; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Mibefradil; Mice; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin; Transcription, Genetic; Xenograft Model Antitumor Assays | 2016 |
Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Cyclopropanes; Female; Humans; Mibefradil; Mice; Mice, Nude; Naphthalenes; Ovarian Neoplasms; RNA Interference; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |